News

rFVIIIFc is based on Biogen Idec’s new and proprietary monomeric Fc-fusion technology. The registrational clinical trial is expected to evaluate the potential of rFVIIIFc to prolong protection from

With this expansion Waltrop capabilities are extended through the addition of solid and semi-solid production to its hormone facility (operational since August 2005) with production areas, separate personnel

Mr Tooman will succeed Elizabeth Larkin and will take up the responsibility for all financial services and information technology services. Mr Tooman joins Ikaria from Enzon Pharmaceuticals, where

The study was a follow-up of three recently completed international clinical studies on short-term venous thromboembolism (VTE) protective medicine in patients undergoing major orthopedic surgery showed 25% reduction

Cempra Pharma paid the milestone following the development of macrolide (CEM-101) for the treatment of respiratory infections. Cempra Pharma has licensed CEM-101 from Optimer Pharma and has completed

Tß4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. The preclinical studies of this multi-functional molecule has shown to promote endothelial

Globally, the pharmaceutical industry is witnessing rapid advancements in processes and technological developments. Automation is emerging as an integral part of nearly all manufacturing processes and pharmaceutical big

The combined drug discovery service is expected to provide access to new capabilities for accelerating drug discovery and improve productivity to the pharmaceutical, biotech and governmental research organisations.

Crucell said that the termination right was triggered by the acquisition of Shantha by sanofi pasteur in July 2009. Whereas, Sanofi pasteur would have to return the commercial